Comprehensive Review on COVID-19 associated Mucormycosis: Diagnosis, Types and Treatment

Neha Manish Munot^1*, Maheshwari Tulsidas Raut²,Ujjwala Yadav Kandekar³, Neeta Rai⁴ and Preeti Vinod Gaikwad⁵

¹Rajmata Jijau Shikshan Prasarak Mandal’s College of Pharmacy, Pune, India.

²Department of Pharmaceutics, Smt. Kashibai Navale College of Pharmacy, Pune, India.

³Department of Pharmaceutics, JSPMs Rajarshi Shahu College of Pharmacy and Research, Pune, India.

⁴Department of Pharmaceutics, School of Pharmacy, Vishwakarma University, Pune, India.

⁵Department of Pharmaceutical Chemistry, KJEI’ Trinity College of Pharmacy, Pune, Maharashtra, India.

Corresponding Author E-mail: nehamunot@yahoo.com

DOI : http://dx.doi.org/10.13005/bbra/3227

ABSTRACT: In the past couple of years, the world has been dealing with a dreadful pandemic known as Covid-19 along with one of the life-threatening infection i.e. mucormycosis. Mucormycosis (Zygomycosis) is a fungal infection caused by a group of molds called mucormycosis. Several clinical cases of mucormycosis have been reported globally during the Covid-19 pandemic. Patients with compromised immunity or uncontrolled diabetics or patients that were given steroid therapy to combat infection due to corona virus were at high risk of acquiring mucormycosis as co-morbidity associated with Covid-19. In the present review, various types of mucormycosis, diagnosis, and treatment strategies are explained as it is associated with high morbidity and mortality. Amphotericin B liposomal formulation was found to be the most widely used to treat mucormycosis. Other antifungal agents and adjuvant therapies were also tried to treat this infection.

KEYWORDS: Antifungal drugs; Mucormycosis (zygomycosis); rhino cerebral sinus

[ HTML Full Text]